Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Status:
Completed
Trial end date:
2005-12-20
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase I/II trial to study the effectiveness of irinotecan in treating patients who
have progressive or recurrent malignant glioma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
North American Brain Tumor Consortium Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins